US Supreme Court declines to hear Omnicef patent case
This article was originally published in Scrip
Executive Summary
The US Supreme Court has declined to hear Astellas Pharma's case against generic drug makers for allegedly infringing a patent for the cephalosporin antibiotic Omnicef (cefdinir), according to the legal site Healthlaw360.com. Having the high court decline a bid for certiorari is not unusual, as the court does not hear many patent cases. Generic drug makers Teva Pharmaceutical Industries, Novartis's Sandoz unit and Lupin all urged the justices not to hear the case.